|
시장보고서
상품코드
2055065
당뇨병성 신증 시장 : 약제 클래스별, 당뇨병 유형별, 투여 경로별, 성별, 연령층별, 병기별, 유통 채널별, 최종사용자별, 지역별Diabetic Nephropathy Market, By Drug Class, By Diabetes Type, By Route of Administration, By Gender, By Age Group, By Disease Stage, By Distribution Channel, By End User, By Geography |
||||||
당뇨병성 신증 시장은 2026년에 37억 4,000만 달러로 추정되며, 2033년까지 58억 1,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 6.5%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 37억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 6.50% | 2033년 시장 규모 예측 : | 58억 1,000만 달러 |
세계 당뇨병성 신증 시장은 더 광범위한 신장학 및 당뇨병 관리 생태계에서 중요한 부분을 차지하며, 당뇨병의 가장 심각한 합병증 중 하나를 다루고 있습니다.
당뇨병성 신증(당뇨병성 신질환이라고도 함)은 당뇨병 환자의 약 20-40%에게 영향을 미치며, 전 세계적으로 말기 신장 질환의 주요 원인이 되고 있습니다. 이 진행성 질환은 장기간 고혈당 상태에 노출됨에 따라 신장 기능이 서서히 저하되며, 치료를 받지 않을 경우 결국 만성 신장 질환이나 신부전으로 이어질 수 있습니다.
이 시장에는 안지오텐신 전환 효소(ACE) 억제제, 안지오텐신 수용체 차단제(ARB), 이뇨제, 칼슘 채널 차단제, 그리고 당뇨병성 신증의 진행과 관련된 특정 경로를 표적으로 하는 새로운 치료법 등의 종합적인 치료법이 포함되어 있습니다.
세계 당뇨병 유병률이 급격히 증가세를 이어가며 전 세계적으로 5억 3,700만 명 이상의 성인이 영향을 받고 있는 가운데, 당뇨병성 신증 시장은 제약 기업, 의료 서비스 제공업체, 규제 당국으로부터 큰 주목을 받고 있습니다. 조기 발견에 대한 인식 제고, 진단 능력 향상, 그리고 혁신적인 치료법 개발이 맞물려 시장의 견실한 성장 궤도에 기여하고 있으며, 전 세계 투자 및 연구개발 활동의 초점이 되고 있습니다.
시장 역학
세계 당뇨병성 신증 시장은 몇 가지 강력한 시장 성장 촉진요인에 의해 견인되고 있습니다. 그중에서도 가장 중요한 것은 전 세계 당뇨병 유병률, 특히 2형 당뇨병의 급격한 증가이며, 이는 당뇨병성 신장 합병증의 발생률 증가와 직접적인 관련이 있습니다. 전 세계적인 고령화, 앉아 있는 시간이 많은 생활 습관, 비만율 증가가 맞물려 당뇨병의 확산을 가속화하고 있으며, 그 결과 신장 질환 관리 솔루션에 대한 수요를 견인하고 있습니다.
의료 종사자와 환자들 사이에서 조기 개입과 정기적인 모니터링의 중요성에 대한 인식이 높아짐에 따라, 선별 검사율이 향상되고 조기 진단이 확대되면서 대상 환자층이 넓어지고 있습니다. 바이오마커의 규명 및 비침습적 모니터링 시스템을 포함한 진단 도구의 기술적 발전으로 인해, 질환의 검출 능력이 향상되었습니다. 한편, SGLT2 억제제나 엔도세린 수용체 길항제 등 새로운 치료 표적에 초점을 맞춘 의약품의 혁신은 치료 패러다임에 혁명을 가져왔습니다.
그러나 시장에는 중대한 제약도 존재합니다. 특히 당뇨병 부담이 가장 큰 개발도상국에서는 첨단 치료법과 진단 절차의 높은 비용으로 인해 치료 접근성이 제한되고 있습니다. 의료 인프라의 부족, 전문 신장 전문의의 부족, 그리고 특정 시장의 미흡한 보험 급여 정책 또한 시장 성장에 있어 추가적인 과제로 작용하고 있습니다. 장기적인 약물 치료에 대한 환자의 순응도 문제와 초기 단계의 당뇨병성 신병증이 무증상이라는 특성 때문에 치료 시작이 늦어지는 경우가 많습니다.
이러한 과제가 있음에도 불구하고, 당뇨병 환자 수가 막대한 신흥 시장, 유전자 프로파일링에 기반한 맞춤형 의료 접근법의 개발, 질병 관리에 인공지능(AI)을 접목하는 것, 그리고 여러 경로를 동시에 표적으로 삼는 병용 요법의 가능성 등 다양한 형태로 큰 기회가 존재합니다. 예방 의료와 가치 기반 헬스케어 모델에 대한 관심이 높아지고 있는 점도 시장 확대를 위한 또 다른 길을 제시하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 당뇨병성 신증 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 당뇨병성 신증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업 및 금융 애널리스트를 포함한 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 당뇨병성 신증 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 당뇨병성 신증 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 당뇨병성 신증 시장 : 당뇨병 유형별, 2021년-2033년
제6장 세계의 당뇨병성 신증 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 당뇨병성 신증 시장 : 성별, 2021년-2033년
제8장 세계의 당뇨병성 신증 시장 : 연령층별, 2021년-2033년
제9장 세계의 당뇨병성 신증 시장 : 질환 진행 단계별, 2021년-2033년
제10장 세계의 당뇨병성 신증 시장 : 유통 채널별, 2021년-2033년
제11장 세계의 당뇨병성 신증 시장 : 최종사용자별, 2021년-2033년
제12장 세계의 당뇨병성 신증 시장 : 지역별, 2021년-2033년
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고 문헌 및 조사 방법
LSH 26.06.22Diabetic Nephropathy Market is estimated to be valued at USD 3.74 Bn in 2026 and is expected to reach USD 5.81 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.74 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.50% | 2033 Value Projection: | USD 5.81 Bn |
The global diabetic nephropathy market represents a critical segment within the broader nephrology and diabetes care ecosystem, addressing one of the most severe complications of diabetes mellitus.
Diabetic nephropathy, also known as diabetic kidney disease, affects approximately 20-40% of patients with diabetes and stands as the leading cause of end-stage renal disease worldwide. This progressive condition involves the gradual deterioration of kidney function due to prolonged exposure to high blood glucose levels, ultimately leading to chronic kidney disease and potential kidney failure if left untreated.
The market encompasses a comprehensive range of therapeutic interventions including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, calcium channel blockers, and emerging novel therapies targeting specific pathways involved in diabetic kidney disease progression.
With the global diabetes prevalence continuing to rise dramatically, affecting over 537 million adults worldwide, the diabetic nephropathy market has gained substantial attention from pharmaceutical companies, healthcare providers, and regulatory authorities. The increasing awareness about early detection, improved diagnostic capabilities, and the development of innovative treatment modalities have collectively contributed to the market's robust growth trajectory, making it a focal point for investment and research activities globally.
Market Dynamics
The global diabetic nephropathy market is propelled by several compelling drivers, with the most significant being the exponential rise in diabetes prevalence worldwide, particularly Type 2 diabetes, which directly correlates with increased incidence of diabetic kidney complications. The aging global population, sedentary lifestyles, and rising obesity rates have created a perfect storm for diabetes proliferation, subsequently driving demand for nephropathy management solutions.
Growing awareness among healthcare professionals and patients about the importance of early intervention and regular monitoring has led to increased screening rates and earlier diagnosis, expanding the addressable patient population. Technological advancements in diagnostic tools, including biomarker identification and non-invasive monitoring systems, have enhanced disease detection capabilities, while pharmaceutical innovations focusing on novel therapeutic targets such as SGLT2 inhibitors and endothelin receptor antagonists have revolutionized treatment paradigms.
However, the market faces significant restraints including the high cost of advanced therapeutic and diagnostic procedures, which limits accessibility particularly in developing regions where diabetes burden is highest. Limited healthcare infrastructure, shortage of specialized nephrologists, and inadequate reimbursement policies in certain markets pose additional challenges to market growth. Patient compliance issues with long-term medication regimens and the asymptomatic nature of early-stage diabetic nephropathy often result in delayed treatment initiation.
Despite these challenges, substantial opportunities exist in the form of emerging markets with large diabetic populations, development of personalized medicine approaches based on genetic profiling, integration of artificial intelligence in disease management, and the potential for combination therapies that target multiple pathways simultaneously. The increasing focus on preventive care and value-based healthcare models presents additional avenues for market expansion.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic nephropathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca plc, Bayer AG, Eli"¯Lilly and Company, Johnson & Johnson, Novartis AG, Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, AbbVie Inc., Abbott Laboratories, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, and Amgen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diabetic nephropathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic nephropathy market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Angiotensin"'Converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Sodium"'Glucose Cotransporter 2 (SGLT2) Inhibitors
- Mineralocorticoid Receptor Antagonists (MRAs)
- Diuretics
- Calcium Channel Blockers
- Others (e.g., GLP"'1 Receptor Agonists, DPP"'4 Inhibitors, Endothelin"'A Receptor Antagonists, Fibrosis/Inflammation Modulators)
- Diabetes Type Insights (Revenue, USD Bn, 2021 - 2033)
- Type 1 Diabetes
- Type 2 Diabetes
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral (injectables/infusions)
- Other routes (e.g., transdermal, novel delivery)
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Disease Stage Insights (Revenue, USD Bn, 2021 - 2033)
- Early Stage
- Moderate Stage
- End-Stage Renal Disease (ESRD)
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Clinics
- Specialty Nephrology Centers
- Home Care/Ambulatory Care
- Other settings (dialysis centers, renal transplant units)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AstraZeneca plc
- Bayer AG
- Eli"¯Lilly and Company
- Johnson & Johnson
- Novartis AG
- Sanofi S.A.
- Merck & Co., Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- AbbVie Inc.
- Abbott Laboratories
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Amgen Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Diabetic Nephropathy Market, By Drug Class
- Global Diabetic Nephropathy Market, By Diabetes Type
- Global Diabetic Nephropathy Market, By Route of Administration
- Global Diabetic Nephropathy Market, By Gender
- Global Diabetic Nephropathy Market, By Age Group
- Global Diabetic Nephropathy Market, By Disease Stage
- Global Diabetic Nephropathy Market, By Distribution Channel
- Global Diabetic Nephropathy Market, By End User
- Global Diabetic Nephropathy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Diabetic Nephropathy Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Angiotensin"'Converting Enzyme (ACE) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Angiotensin II Receptor Blockers (ARBs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sodium"'Glucose Cotransporter 2 (SGLT2) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mineralocorticoid Receptor Antagonists (MRAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (e.g., GLP"'1 Receptor Agonists, DPP"'4 Inhibitors, Endothelin"'A Receptor Antagonists, Fibrosis/Inflammation Modulators)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Diabetic Nephropathy Market, By Diabetes Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Diabetic Nephropathy Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral (injectables/infusions)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other routes (e.g., transdermal, novel delivery)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Diabetic Nephropathy Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Diabetic Nephropathy Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Diabetic Nephropathy Market, By Disease Stage, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Early Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Moderate Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- End-Stage Renal Disease (ESRD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Diabetic Nephropathy Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Diabetic Nephropathy Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Nephrology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Care/Ambulatory Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other settings (dialysis centers, renal transplant units)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Diabetic Nephropathy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User , 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli"¯Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
